William McGann, MD
Critical Care Medicine · Lawrenceville, GANPI 1699751925
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 170 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,191, 3.5 times the $336 reported in 2019.
Across 170 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$770
- Insmed, Inc.$362
- Boehringer Ingelheim$357
- AstraZeneca$256
- Regeneron Healthcare Solutions, Inc.$211
- Grifols USA, LLC$191
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,32399%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 47 | $770 |
| Insmed, Inc. | 13 | $362 |
| Boehringer Ingelheim | 14 | $357 |
| AstraZeneca | 15 | $256 |
| Regeneron Healthcare Solutions, Inc. | 10 | $211 |
| Grifols USA, LLC | 8 | $191 |
| Sanofi | 6 | $174 |
| Amgen | 6 | $104 |
| Merck | 4 | $103 |
| Viatris Specialty LLC | 4 | $90 |
| Mylan Specialty L.p. | 5 | $90 |
| Novartis | 4 | $68 |
| Harmony Biosciences LLC | 2 | $47 |
| Sunovion Pharmaceuticals Inc. | 3 | $46 |
| Pfizer | 3 | $46 |
| Verona Pharma, Inc. | 2 | $40 |
| United Therapeutics Corporation | 2 | $40 |
| AbbVie | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 2 | $36 |
| Resmed Corp | 2 | $29 |
| Johnson & Johnson | 2 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Baxter Healthcare | 1 | $18 |
| Portola Pharmaceuticals, LLC | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| La Jolla Pharmaceutical Company | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Gilead | 1 | $14 |
How this compares
$3,373 in reported general payments places this provider in the 80th percentile of 265 critical care medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 50 | $669,972 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 185 | $129,688 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 132 | $125,121 |
| Spiriva RespimatTiotropium Bromide | 143 | $125,111 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 101 | $75,573 |
| EliquisApixaban | 50 | $48,822 |
| Incruse ElliptaUmeclidinium Bromide | 85 | $45,348 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $35,951 |
| SymbicortBudesonide/Formoterol Fumarate | 106 | $34,449 |
| Advair HfaFluticasone Propion/Salmeterol | 67 | $33,974 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $30,894 |
| Arnuity ElliptaFluticasone Furoate | 89 | $25,912 |
| Spiriva HandihalerTiotropium Bromide | 20 | $18,622 |
| Pirfenidone | 24 | $17,861 |
| XareltoRivaroxaban | 22 | $14,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $357 | $879,786313 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta | $770 | $362,019543 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere | $256 | $79,171159 claims |
| PfizerEliquis | $46 | $48,82250 claims |
| Johnson & JohnsonXarelto | $27 | $14,67222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 265 critical care medicine providers in Georgia.
Other critical care medicine in Lawrenceville
- Rajesh JasaniLawrenceville$8K
- Paul WeinbergLawrenceville$6K
- Lawrence KaplanLawrenceville$4K
- Sarah HayatLawrenceville$3K
- Salman FidahusseinLagrange$852K
- Bruce FriedmanAugusta$629K
- Gregory MauldinSnellville$221K
- Ramzy RimawiAtlanta$72K
- Rafael Alba YunenBrunswick$58K
- April McDonaldGainesville$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.